Daré Bioscience, Inc. filings document a women’s health biotechnology issuer with product and pipeline disclosures, operating-result updates, and capital-structure activity. Recent 8-K reports cover financial results, Regulation FD presentations, and unregistered sales tied to a Regulation A unit offering composed of Series A Convertible Preferred Stock and warrants to purchase common stock.
Proxy and governance filings describe annual meeting matters, director elections, executive compensation, equity awards, board classification, and stockholder voting procedures. The record also includes disclosure around offering statements, preferred-stock conversion terms, warrant exercise terms, and financing activity associated with advancing women’s health products and clinical programs.
Kelley Susan L. reported acquisition or exercise transactions in this Form 4 filing.
Dare Bioscience, Inc. reported that director Susan L. Kelley received a grant of 23,696 shares of common stock in the form of restricted stock units (RSUs). These RSUs were granted in lieu of cash compensation for her service on the board and its committees.
Each RSU represents a right to receive one share of Dare Bioscience common stock when vested, and the RSUs vest on January 4, 2027. Following this award, Kelley’s reported direct holdings total 23,696 shares.
Dare Bioscience director Gregory W. Matz received a grant of 30,805 shares of common stock in the form of restricted stock units as compensation for serving on the company’s board and its committees. Each RSU converts into one share when it vests on January 4, 2027. After this award, he holds 30,847 shares directly.
RASTETTER WILLIAM H reported acquisition or exercise transactions in this Form 4 filing.
Dare Bioscience director William H. Rastetter received an equity grant of 38,862 restricted stock units (RSUs). The RSUs were granted in lieu of cash compensation for his service on the board of directors and its committees, at a stated price of $0.00 per share. Each RSU represents a contingent right to receive one share of common stock upon vesting, which occurs on January 4, 2027. Following this grant, he directly holds 39,721 shares of Dare Bioscience common stock.
Steele Robin Joan reported acquisition or exercise transactions in this Form 4 filing.
Dare Bioscience director Robin Joan Steele received an equity grant instead of cash fees for board service. She was awarded 26,540 restricted stock units, each representing one share of common stock when vested, at a stated price of $0.00 per unit. Following this grant, she directly holds 47,055 shares, including the new RSUs. The RSUs vest on January 4, 2027, aligning her compensation more closely with Dare Bioscience’s long-term share performance.
Dare Bioscience, Inc. furnished a new corporate investor presentation as Exhibit 99.1 under a Regulation FD disclosure. The presentation is dated June 22, 2026 and will be used in meetings with securities market participants and others starting that same date.
The company plans to post the presentation in the Investors section of its website under “Presentations, Events & Webcasts.” The information in the presentation and in this disclosure is being furnished, not filed, so it is not subject to Section 18 liability and is not automatically incorporated into other SEC filings.
Daré Bioscience, Inc. reported the results of its June 11, 2026 annual stockholder meeting. Stockholders approved an amendment to the 2022 Stock Incentive Plan to increase shares available for issuance by 1,500,000, providing additional equity for employee and director compensation.
All director nominees were re-elected, the independent auditor Haskell & White LLP was ratified for the 2026 fiscal year, and the advisory vote on executive compensation passed. Stockholders indicated a preference to hold the advisory say-on-pay vote every year, and approved the potential future issuance of common stock under the existing equity line with Lincoln Park Capital Fund, LLC.
Dare Bioscience director William H. Rastetter received a grant of stock options for 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036. They vest in full on the earlier of the first anniversary of the grant date or immediately before the company’s first annual shareholder meeting after the grant date, subject to his continued board service. The options also become fully exercisable upon a change in control of Dare Bioscience.
Dare Bioscience director Susan L. Kelley received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036. Following this award, she holds 10,000 stock options directly from this grant.
The option will vest in full on the earlier of the first anniversary of the grant date or immediately before the company’s first annual stockholders’ meeting after the grant, as long as she continues serving as a director. It will also become fully exercisable upon a change in control of Dare Bioscience.
Dare Bioscience, Inc. director Robin Joan Steele received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036.
The option will vest in full on the earlier of the first anniversary of the June 11, 2026 grant date or immediately prior to the company’s first annual meeting of stockholders occurring after that date, subject to Steele’s continued service as a director. The option also becomes fully exercisable upon a change in control of the company. Following this grant, Steele holds 10,000 stock options directly.
Dare Bioscience, Inc. director Gregory W. Matz received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036. They vest in full on the earlier of the first anniversary of the grant date or immediately before the first annual stockholder meeting after the grant date, subject to his continued board service, and become fully exercisable upon a change in control.